Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am expecting another upgrade and/or target price bump from Wainwright (or even other analysts) soon.
-vg_future
The timing seems to be an obligation from past that they want/have to close off. Of course, money is always useful for upcoming trials, commercialization. But, I was hoping for some more NEWS items to build the price up further before such offering. Pretty small amount of shares though and see where ANVS and SAVA are trading after their offers at $50.
Price being lower than the market price on the day of closing is normal.
-vg_future
tredenwater2, I wouldn't put anything past these guys on wall street. SAVA might have put out NEWS today either to keep its own traction or steal the show from a competitor (in this case AVXL). They keep milking the same NEWS with multiple minor updates...setting up the company for a take over.
It might be the most probable/possible reason considering SAVA's history on how they re-purposed (reworked) their data to make it presentable (could fit well with Biogen's culture ).
-vg_future
Thanks Tdeank1.
imho, yep. As another poster opined (and I totally agree)...it is good not to oversaturate the NEWS, but still make it as a statement in another piece of great NEWS/PR and in the right context.
-vg_future
baltimorebullet, I agree. If he has other major PRs, it is best not to oversaturate...just make a statement and in the right context. Say if he wants to say something along the lines of
- The interim ALZ phase 2b/3 results are great...
- discussing/discussed with FDA...
- starting final phase of ALZ trials...
btw, we have already completed enrollment.
-vg_future
“Completed enrollment”...great NEWS tidbit hidden in the PR today.
From the PR -
This independent paper highlights the understanding of the relevance of utilizing sigma-1 receptor activation as compensatory mechanism to chronic CNS diseases, currently tested in late-stage placebo-controlled ANAVEX®2-73 Phase 2b/3 clinical Alzheimer's disease study, which recently completed enrollment, as well as in Parkinson’s disease dementia (ANAVEX2-73-PDD-001) and ongoing Rett syndrome program (ANAVEX2-73-RS-001/002/003)”, said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
-vg_future
If this isn't already posted...Dr. Joel Perlmutter on CNN about his decision and FDA's decision.
https://www.cnn.com/videos/health/2021/06/11/dr-joel-perlmutter-intv-fda-advisor-resign-alzheimers-aducanumab-sot-nr-vpx.cnn
-vg_future
nidan7500, yes, you are right. AVXL has to just go above this noise so that true analysts start following it and the whole investment community (and more importantly the patients) become aware of it
-vg_future
nidan7500, want to see the audacity of this manipulation/pumping/campaigning......it is a motley fool article written by the same guy and published on Monday and again today. See the links below (first one is from today and the second from Monday when BIIB got approved)
Today's article:
https://www.fool.com/investing/2021/06/11/ignore-biogen-3-reasons-these-stocks-will-be-bette/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Monday article:
https://www.fool.com/investing/2021/06/07/forget-biogen-these-2-alzheimers-drug-stocks-could/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Don't know how many more times it was run (caught these two at first glance) or will run.
-vg_future
Steady_T, agreed. There will definitely be a bidding war which will help AVXL....from a selfish perspective of having vested in here (financially and emotionally), I would still love to see AVXL in the driver's seat rather than having to pick best of the outstanding bids.
-vg_future
I would love to see AVXL in the driver's seat stepping on the gas. Soon I hope.
-vg_future
Yes, I do have that concern about these companies (also about BIIB as some here have mentioned). They will build their arsenal with the aid from wallstreet crooks (and manipulators) and use it on genuine candidate like AVXL. Hope AVXL becomes big and strong to avoid any unsolicited/hostile maneuvers.
-vg_future
Yes, possible. There is so much manipulation in this stock (and others as well) that I just wish that Dr.Missling comes out with the right NEWS at the right moment to get the maximum benefit to the share holders (of course, also kick the #### of the manipulators).
-vg_future
The wallstreet promoters are pushing/pumping SAVA and ANVS again....I see repetition articles bombarding the wires to get the traction. I don't care if some other stock is getting some traction, but doesn't feel or seem right that none of these firms are doing enough research to find that AVXL is far ahead of these guys. One day...pretty soon..one day...it will happen.
-vg_future
Kb1123, most likely a change in his role (maybe he is out as a Director). He exercised all his options accumulated over 5 or 6 yrs and sold them all. Not a big deal I would say if he is leaving the board (or asked to leave).
JMHO,
vg_future
Thanks TC65. Appreciate your time and help.
-vg_future
Interesting that ANVS had to release the results/data in two installments to get the reaction that they are getting today. I can't wait for Anavex to release the details of the PDD studies which showed (as per Anavex corp presentations) significant improvements.
Check the ANVS 5 days chart to see the reaction to ANVS PRs from the same study:
ANVS two days back - which didn't get much reaction
https://finance.yahoo.com/news/annovis-bio-announces-positive-phase-203000110.html
ANVS today PR - that gave the booster shot today ( )
- https://finance.yahoo.com/news/annovis-bio-announces-positive-phase-120100640.html
Anavex, in addition to the great studies and supporting results/data, needs to do manage some perception issues as well maybe...I am just hoping that the data will speak for itself without the need for any maneuvering.
-vg_future
Lots of eye-poppers...love that.
GLTA,
vg_future
Thanks ElsaSara. Yes, March 31st DSMB PR stated over 92% enrolled.
PR:
https://finance.yahoo.com/news/anavex-life-sciences-reports-data-110000348.html
So, a little over one month got us over 98...so, we should be very close to the finish line...Next week? Let's see.
-vg_future
AVXL short interest grew by another 500K.
https://www.nasdaq.com/market-activity/stocks/avxl/short-interest
Thanks Jager997. Anavex can use the terminology (with this kind of definition/explanation that you have linked) to keep it under the covers until all the details are worked out. Lot of action behind the scenes....waiting eagerly for the curtain lift.
vg_future
Denali-Biogen PD trial's (Phase 1) data out today..late stage by end of 2021. We are far advanced than this and the market will open its eyes to this soon. Very eventful next few months and rest of the year for Anavex.
-vg_future
So, now that we are close to the great readouts, it is the side effects speculation. Very sneaky if not obvious. Missling will put an end to this with the readouts, peer reviews and approvals.
Waiting for the big jump in AVXL soon and the right exposure to the drug, the approach, and potential.
-vg_future
Thinking out loud...maybe FDA can give (as a last resort if up against the wall...and if push comes to shove) conditional approval for Biogen since they are saying (actually, more like warning and bullying) that nothing else is out there. Condition: The moment another drug proves better efficacy, Biogen's approval should be revoked. However, this approach could be dangerous, because before someone else comes up with a better treatment...Biogen's drug could do lot of damage and it might not be a simple task to pull the drug out and people off of the treatment.
JMHO,
vg_future
Steady_T, agreed. That would be a good approach. A treatment claim can be made once any supporting data is available.
-vg_future
Journey of treatment has to be good....so, treating the symptoms will be equally attractive (maybe more in some cases) while the root cause is treated.
The tweet definitely looks good and is a great teaser.
To put it in the right context, if Memory loss is a symptom in Parkinson's...improving the memory (as stated by Anavex) can qualify as a symptom treatment.
If lack of sleep is a symptom for PD, improving sleep can qualify as a symptom treatment.
There could be lot of other symptoms that are treated by A2-73, but I picked the two obvious ones from layman perspective.
JMHO,
vg_future
Thanks boi568. Very good explanation and possibility.
kevindenver, her venture partner experience could and would go a long way in Anavex's favor. Let's see how this (and these) cards play out.
-vg_future
boi568, it could be even more faster/sooner considering all the new sites they have opened.
JMHO,
vg_future
You (and Steady_T) are right. A small city might mean covering all types of population for a larger trial (P3 or P4).
-vg_future
WolfofMia, I took your pre-screening comment as referring genetic screening..in which case...you are right. I don't think they are doing genetic profiling before taking someone into trials. The other pre-screening conditions that Jager mentioned would be the conditions for other regular trials as well so that the symptoms related to the specific trials can be monitored properly.
JMHO,
vg_future
Importance of last week's PR. PEER REVIEWED ARTICLE ...which means it is not only the company or Missling claiming success....esteemed scientific community is also vouching for the data. Keep repeating the term...PEER REVIEWED...then the importance and the future of the drug in the CNS arena will be understood.
-vg_future
This seems like a manipulation...particularly considering the great NEWS yesterday. with so much good NEWS around, I just wish the manipulators get caught with their pants down. I can understand some profit taking from traders, but this seems a bit more than that. All these happening while SAVA gets a PT boost to 110.
It is Anavex's analysts' turn to read what was revealed by the experts yesterday and do the necessary...or else they will soon be wondering how they missed the boat on Anavex.
-vg_future
Another important thing...if Hampel is/was part of the paper, the comparison against Eisai's own studies puts it in a perspective...the right and favorable one for Anavex.
JMHO,
vg_future
TempePhil, thanks for the comparative analysis. Very well put. It is only matter of time before the world finds/accepts the benefits of Anavex’s drug.
-vg_future
Thanks for the comparison. I wish the independent scientific papers do similar analysis and present the conclusions. It would be a great platform. It will make FDA’s life an decisions easy.
-vg_future
Tradeherpete, yes. Side effects are alarming. Anavex comes way ahead from this perspective as well...no alarming side effects.
vg_future
Pretty soon Anavex would/should put out a PR like this about memory improvement in PDD patients. This is a great accomplishment that went unnoticed (or didn’t get enough coverage) on wallstreet.
Eli Lilly’s drug could slow cognitive decline.....which means that memory stayed at the same point during the trials as opposed to the placebo group....whereas Anavex’s drug not only slowed but also reversed the cognitive decline. This should put it in the right perspective for the scientific community and wallstreet with patients gaining ultimately.
Eli’s announcement
https://finance.yahoo.com/news/lilly-alzheimers-drug-shows-benefit-114314048.html
Anavex’s recent slides have the details on the PDD improvements.
-vg_future
In a way - it is kind of reversing the disease (memory improvements when compared the point when they started the medication) from deteriorating memory perspective.
Who knows...with prolonged treatment...it might even cure it. I understand that we cannot claim it yet because of the time needed to prove it and get official stamp. Also, there will be an age aspect to it that will muddy the waters. So, memory improvement claim is pretty to go with.
JMHO
vg_future